PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28881756-5	2017	After treatment with FAPalpha inhibitor PT-100, senescent rate was decreased (P = 0.001), Treg/Th17 was up-regulated (P = 0.024).	talabostat	40-46	fibroblast activation protein alpha	Homo sapiens	21-29	
27689014-9	2016	In support of these results we observed no enzymatic degradation of human FGF21 at either end of the protein when FAP was inhibited in vitro by TB.	talabostat	144-146	fibroblast activation protein alpha	Homo sapiens	114-117	
18032930-0	2007	Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.	talabostat	44-54	fibroblast activation protein alpha	Homo sapiens	67-96	
18032930-2	2007	The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer.	talabostat	68-78	fibroblast activation protein alpha	Homo sapiens	23-26	
18032930-2	2007	The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer.	talabostat	68-78	fibroblast activation protein alpha	Homo sapiens	113-116